Prevalence of genital warts among sexually transmitted disease clinic patients-sexually transmitted disease surveillance network, United States, january 2010 to december 2011

Sexually Transmitted Diseases

Volumn 41, Issue 2, 2014, Pages 89-93

  Llata, Eloisa ^a   Stenger, Mark ^a   Bernstein, Kyle ^b   Guerry, Sarah ^c   Kerani, Roxanne ^d   Pugsley, River ^e   Pathela, Preeti ^f   Tabidze, Irina ^g   Weinstock, Hillard ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^c Los Angeles Department of Public Health   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e VIRGINIA DEPARTMENT OF HEALTH   (United States)

^f NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^g CHICAGO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; CHILD; CHLAMYDIA TRACHOMATIS; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ELIMINATION; DISEASE SURVEILLANCE; FEMALE; GENITAL WART PREVALENCE; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEN WHO HAVE SEX WITH MEN; MEN WHO HAVE SEX WITH WOMEN; MIDDLE AGED; NEISSERIA GONORRHOEAE; PREVALENCE; SCHOOL CHILD; SEXUAL BEHAVIOR; SEXUAL MINORITY; SEXUALLY TRANSMITTED DISEASE; SEXUALLY TRANSMITTED DISEASE SURVEILLANCE NETWORK; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CONDYLOMATA ACUMINATA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PREVALENCE; SENTINEL SURVEILLANCE; SEXUAL BEHAVIOR; UNITED STATES; VACCINATION;

EID: 84892953121     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000077     Document Type: Article

References (27)

1. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10:122-163.
2. Dempsey AF, Koutsky LA. National burden of genital warts: a first step in defining the problem. Sex Transm Dis 2008; 35:361-362.
3. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36:1397-1403.
4. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2011. Atlanta: U.S. Department of Health and Human Services; 2012.
5. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: Analytic framework and review of the literature. Pharmacoeconomics 2005; 23:1107-1122.
6. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: Perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998; 9:571-578.
7. Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37:3316-3322.
8. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(suppl 3):S3/35-41.
9. Munoz N. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 2000; 19:1-5.
10. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillo-mavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
11. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
12. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007; 56:1-24.
13. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in malesVAdvisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705-1708.
14. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): A cohort study. Lancet 2011; 377:932-940.
15. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ (Clinical research ed.) 2010; 341:c3493.
16. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401-411.
17. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papil-lomavirus vaccination and trends in genital warts in Australia: Analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
18. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human pap-illomavirus vaccine availability. J Infect Dis 2012; 206:860-866.
19. Bauer HM, Wright G, Chow J. Evidence of human papillomavi-rus vaccine effectiveness in reducing genital warts: An analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012; 102:833-835.
20. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: Potential impact of human papillomavirus vaccination. Am J of Public Health 2013; 103:1428-1435.
21. Sturgiss EA, Jin F, Martin SJ, et al. Prevalence of other sexually transmissible infections in patients with newly diagnosed anogenital warts in a sexual health clinic. Sex Health 2010; 7:55-59.
22. Brackbill RM, Sternberg MR, Fishbein M. Where do people go for treatment of sexually transmitted diseases. Fam Plann Perspect 1999; 31:10-15.
23. Golden MR, Kerndt PR. Improving clinical operations: Can we and should we save our STD clinics? Sex Transm Dis 2010; 37:264-265.
24. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital wartsYrelated healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31:748-752.
25. Hoy T, Singhal PK, Willey VJ, et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009; 25:2343-2351.
26. Dinh TH, Sternberg M, Dunne EF, et al. Genital warts among 18-to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008; 35:357-360.
27. Hariri S, Unger ER, Sternberg M. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. J Infect Dis 2011; 204:566-573.